Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.5K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.5K
Continuing Care01:25

Continuing Care

2.1K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
2.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Does age matter? Optimizing AML treatment in older adults.

Blood advances·2026
Same author

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Blood advances·2026
Same author

Exploratory association of muscle and adipose tissue indices with clinical outcomes in aggressive lymphomas.

Cancer·2026
Same author

Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.

Blood·2026
Same author

A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.

Blood advances·2025

Related Experiment Video

Updated: Apr 8, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

17.2K

Beyond age: Frailty-guided care in hematologic malignancies.

Reed Friend1, P Connor Johnson2, Daphne Campbell3

  • 1Division of Hematology, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.

Cancer
|April 7, 2026
PubMed
Summary

Frailty assessment in blood cancers predicts treatment outcomes and toxicity. Integrating frailty measures improves care for vulnerable patients, enhancing benefits and quality of life.

Keywords:
acute leukemiaaggressive lymphomasfrailfrailty indices, hematologic malignanciesmultiple myeloma

More Related Videos

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

1.6K
Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.6K

Related Experiment Videos

Last Updated: Apr 8, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

17.2K
Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

1.6K
Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.6K

Area of Science:

  • Gerontology
  • Hematology
  • Oncology

Background:

  • Frailty, a measure of physiological reserve, is distinct from chronological aging.
  • Frailty predicts adverse outcomes such as toxicity, treatment discontinuation, and survival in hematologic malignancies.

Purpose of the Study:

  • To synthesize current frailty assessment tools.
  • To summarize evidence of frailty's impact in multiple myeloma, acute myeloid leukemia, and aggressive lymphomas.

Main Methods:

  • Literature synthesis of contemporary frailty tools.
  • Review of disease-specific evidence in key hematologic malignancies.

Main Results:

  • Frailty assessment is crucial for predicting patient outcomes in hematologic cancers.
  • Evidence highlights the role of frailty in multiple myeloma, AML, and lymphomas.

Conclusions:

  • Integrating frailty measures into clinical practice can guide decision-making for vulnerable patients.
  • Incorporating frailty assessment optimizes therapeutic benefits and enhances patient quality of life.